ERBB2 and osteoporosis: As anti-HER2 treatment as a monotherapy is not covered by health insurance in Korea, we evaluated its effectiveness by comparing the incidence of osteoporosis in the patients receiving anti-HER2 therapy with those not receiving anti-HER2 therapy, irrespective of whether they received any other treatment.